Interview with Prof. Pier Paolo Piccaluga: Bridging Molecular Insights and Clinical Practice in Hematologic Malignancies
On August 8, 2025, Journal of Cancer Metastasis and Treatment (JCMT) had the honor of interviewing Associate Editor Prof. Pier Paolo Piccaluga, an internationally recognized expert in molecular oncology and hematologic malignancies. In this conversation, Prof. Piccaluga shared his latest research insights, perspectives on translational medicine, and advice for the next generation of researchers.
Watch the following video for expert insights from Prof. Pier Paolo Piccaluga:
Interview Questions:
Q1: Prof. Piccaluga, your work has significantly deepened our understanding of the molecular mechanisms underlying acute myeloid leukemia and other hematologic malignancies. Could you share which current research areas excite you the most, and what continues to drive your passion in this field?
Q2: Bridging basic research and clinical application is a major challenge in cancer biology. In your experience, what are the key barriers to successful translational research? How do you see technologies such as Artificial Intelligence, multi-omics and single-cell analysis advancing leukemia research?
Q3: As an experienced scientist and mentor, what core values or principles do you believe young researchers in hematology should uphold? What guidance would you offer to help them become future leaders in academic medicine?
About the Interviewee:
Prof. Pier Paolo Piccaluga, Professor of Pathology, University of Bologna, Bologna, Italy.
Prof. Piccaluga's research focuses on the molecular pathogenesis of acute myeloid leukemia, lymphomas, and other hematologic malignancies. By applying genomic and transcriptomic analyses, his group seeks to identify diagnostic biomarkers and novel therapeutic targets. Prof. Piccaluga has authored 264 high-impact publications, with a cumulative 13298 citations, significantly contributing to the advancement of precision medicine.
Editor: Frida Zhai
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Journal of Cancer Metastasis and Treatment
